^
Association details:
| Biomarker: | TMEM87A-RASGRF1 fusion + TP53 R273H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer
Excerpt:
...received sunitinib 50 mg daily per protocol….identified the aforementioned TP53 mutation but no apparent oncogenic variant....The expression levels of the genes involved in the putative fusion protein in the responder showed TMEM87A at 147.37 FPKM and RASGRF1 at 20.16 FPKM...Objective measurement by a blinded radiologist identified that target disease (hilar lymph node) responded gradually on therapy, shrinking from 19.2mm (short axis) to 9.5mm at time of best response after 33 months of sunitinib (Figure 2). Response was durable and was maintained for the time she remained on study, totaling 36 months.
DOI:
10.1158/1078-0432.CCR-20-0397
Trial ID:
